Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Apple, Comcast, Nike, Medtronic and

Read MoreHide Full Article

For Immediate Release

Chicago, IL – September 30, 2019 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Apple (AAPL - Free Report) , Comcast (CMCSA - Free Report) , Nike (NKE - Free Report) , Medtronic (MDT - Free Report) and (CRM - Free Report) .

Here are highlights from Friday’s Analyst Blog:

Top Stock Reports for Apple, Comcast and Nike

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple, Comcast and Nike. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Apple’s shares have outperformed the broader S&P 500 Index in the past six months (-16.5% vs. 6.1%). The Zacks analyst believes that the company’s focus on strengthening the Services business and a strong slate of upcoming app releases, including its streaming service Apple TV+, are key catalysts.

The company is also expected to benefit from the launch of latest iPhones, refreshed Macbook, iPad and Apple Watch product lines. Apple Arcade is anticipated to boost the company’s footprint in the video game space. However, the ongoing U.S.-China trade war does not bode well for the company.

Further, legal woes have increased due to a lawsuit by customers related to App Store charges. The company has also been accused of unfair practices by Spotify. These are significant headwinds, at least for the near term.

Shares of Comcast have gained 6.2% in the past three months, outperforming the Zacks Cable Television industry’s rise of 2.2%. The Zacks analyst believes that the company is benefiting from solid growth in the number of residential and business services high-speed Internet customers.

The company’s strategy of providing high-speed Internet at an affordable cost is playing a key role in improving customer experience. This will continue to boost revenue per customer on a monthly basis and retention rate. Robust performance of NBC and Telemundo is noteworthy.

Additionally, Sky’s content strength is expected to drive subscriber base in Europe. Further, increase in digital video sales is a key catalyst. However, Comcast continues to lose video subscribers due to cord-cutting. Moreover, a high debt level is a headwind.

Nike’s shares have gained 24.3% year to date, outperforming the Zacks Shoes and Retail Apparel industry’s rise of 23.2% over the same period. The Zacks analyst believes that the company’s performance has been driven by a robust surprise trend stemming from the execution of Consumer Direct Offense, and strength in Wholesale and Nike Direct businesses.

First-quarter fiscal 2020 marked the 10th straight quarter of top-line beat for the company, with earnings beat in 29 of the last 30 quarters. Further, it expects results for fiscal 2020 to be driven by brand recognition, robust innovation pipeline, and positive response from Nike Direct and wholesale partners. However, higher SG&A expenses and tax rate, as well as adverse currency are headwinds.

The company expects SG&A expenses to increase in high single digits in second-quarter fiscal 2020. Further, the company is likely to witness prominent impact of the recently-enacted tariffs in the fiscal second quarter, which should partly mar gross margin.

Other noteworthy reports we are featuring today include Medtronic and

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

 Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                            

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Published in